Overview
Cognito Therapeutics is developing non-invasive sensory stimulation therapies using 40Hz gamma frequency light and sound to target the neurological mechanisms underlying Alzheimer's disease. Their OVERTURE Phase 3 clinical trial is evaluating the Cognito Therapy System for slowing cognitive and functional decline in mild-to-moderate Alzheimer's patients.
More in Cognitive Health
Latest industry news
ReVision Implant Secures €4 Million to Advance Next-Generation Visual Neuroprosthetics
2026-07-25 · Funding
Flourish Emerges from Stealth with Bezos and Google Ventures Backing to Advance Neuroscience Therapeutics
2026-07-24 · Funding
Science Corp. Launches Prima BCI Implant in Europe, Bringing Vision Restoration to a New Market
2026-07-23 · Product
First Able-Bodied Individuals Receive Brain-Computer Implants in Landmark Expansion of BCI Eligibility
2026-07-22 · Research
Company details
Category
💭 Cognitive Health
Location
Cambridge, MA, USA
Funding
Series C · $73M+
Website
cognitotx.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →